223 related articles for article (PubMed ID: 37128788)
21. AIP and the somatostatin system in pituitary tumours.
Ibáñez-Costa A; Korbonits M
J Endocrinol; 2017 Dec; 235(3):R101-R116. PubMed ID: 28835453
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin receptors in normal and acromegalic somatotroph cells: the U-turn of the clinician to immunohistochemistry report - a review.
Ionovici N; Carsote M; Terzea DC; Predescu AM; Rauten AM; Popescu M
Rom J Morphol Embryol; 2020; 61(2):353-359. PubMed ID: 33544787
[TBL] [Abstract][Full Text] [Related]
23. "Silent" thyrotropin (TSH) expression in acromegaly and clinically non-functioning pituitary adenomas.
Pawlikowski M; Pisarek H; Jaranowska M; Radek M; Winczyk K; Kunert-Radek J
Endokrynol Pol; 2016; 67(5):515-518. PubMed ID: 27403655
[TBL] [Abstract][Full Text] [Related]
24. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly.
Fougner SL; Casar-Borota O; Heck A; Berg JP; Bollerslev J
Clin Endocrinol (Oxf); 2012 Jan; 76(1):96-102. PubMed ID: 21722151
[TBL] [Abstract][Full Text] [Related]
25. Role of Receptor Profiling for Personalized Therapy in a Patient with a Growth Hormone-Secreting Macroadenoma Resistant to First-Generation Somatostatin Analogues.
Alexandraki KI; Papadimitriou E; Mavroeidi V; Kyriakopoulos G; Xydakis A; Papaioannou TG; Kolomodi D; Kaltsas GA; Grossman AB
J Pers Med; 2019 Nov; 9(4):. PubMed ID: 31731613
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
27. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
[TBL] [Abstract][Full Text] [Related]
28. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
29. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
[TBL] [Abstract][Full Text] [Related]
30. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern.
Kasuki L; Wildemberg LE; Neto LV; Marcondes J; Takiya CM; Gadelha MR
Eur J Endocrinol; 2013 Aug; 169(2):217-23. PubMed ID: 23749849
[TBL] [Abstract][Full Text] [Related]
31. Pituitary adenomas producing growth hormone in acromegalic patients.
Smallman LA; Dunn PJ; Curran RC; London DR
J Clin Pathol; 1984 Apr; 37(4):382-9. PubMed ID: 6368603
[TBL] [Abstract][Full Text] [Related]
32. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
[TBL] [Abstract][Full Text] [Related]
33. Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas.
Heng L; Liu X; Jia D; Guo W; Zhang S; Gao G; Gong L; Qu Y
Clin Endocrinol (Oxf); 2021 Jul; 95(1):134-142. PubMed ID: 33738801
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly.
Zawada NB; Kunert-Radek J; Pawlikowski M; Pisarek H; Radek M
Endokrynol Pol; 2016; 67(3):292-8. PubMed ID: 27345147
[TBL] [Abstract][Full Text] [Related]
35. Somatostatin receptor ligands in the treatment of acromegaly.
Gadelha MR; Wildemberg LE; Bronstein MD; Gatto F; Ferone D
Pituitary; 2017 Feb; 20(1):100-108. PubMed ID: 28176162
[TBL] [Abstract][Full Text] [Related]
36. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Colao A; Auriemma RS; Pivonello R
Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
[TBL] [Abstract][Full Text] [Related]
37. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
39. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
40. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
